+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Zika Virus - Industry Response to Disease Outbreaks Case Study

  • PDF Icon

    Report

  • 25 Pages
  • April 2020
  • Region: Global
  • GlobalData
  • ID: 5117420
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the pharmaceutical industry to develop interventions to curb these potential disasters. This case study analyzes how the industry responded to the Zika outbreak, and how it compares and contrasts to the current COVID-19 outbreak.

Compare and contrast the pharmaceutical industry's response to a previous outbreak (Zika) to that for COVID-19.

Scope
  • Development landscape and industry response to outbreaks

Reasons to Buy
  • Understand the global epidemiology of COVID-19
  • Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
  • Access an overview of the pipeline for therapeutics and vaccines
  • Stay up to date on available efficacy data for pipeline-stage products
  • View the clinical trials landscape by across key attributes
  • Get up to speed on highlights in deal-making trends, particularly public-private partnerships
  • Monitor top trends in social media coverage

Table of Contents

1 Executive Summary
1.1 Report Scope
1.2 Navigate the COVID-19 Outbreak with Pharma’s COVID-19 Dashboard
1.3 Monitor the COVID-19 Outbreak with Epidemiology Indicators
2 Epidemiology
2.1 Epidemiology: Snapshot as of March 25, 2020
2.2 Epidemiology: Disease Trajectory as of March 25, 2020
2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020
2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020
2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020
2.6 Epidemiology Forecast: United States
3 Pipeline Overview
3.1 Pipeline Therapeutics: Breakdown by Phase
3.2 Pipeline Therapeutics: Breakdown by Molecule Type
3.3 Pipeline Therapeutics: Breakdown by Type of Developer
3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
3.5 Pipeline Therapeutics: Preclinical-Stage Candidates
3.6 Pipeline Therapeutics: Currently Available Data
3.7 Pipeline Vaccines: Breakdown by Phase
3.8 Pipeline Vaccines: Breakdown by Developer Type
3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
4 Pipeline Overview
4.1 Pipeline Therapeutics: Breakdown by Phase
4.2 Pipeline Therapeutics: Breakdown by Molecule Type
4.3 Pipeline Therapeutics: Breakdown by Type of Developer
4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
4.5 Pipeline Therapeutics: Preclinical-Stage Candidates
4.6 Pipeline Therapeutics: Currently Available Data
4.7 Pipeline Vaccines: Breakdown by Phase
4.8 Pipeline Vaccines: Breakdown by Developer Type
4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
5 Clinical Trials
5.1 Clinical Trials: Breakdown by Phase
5.2 Clinical Trials for Therapeutics and Vaccines
5.3 Clinical Trials: Overview by Region
5.4 Clinical Trials for Therapeutics: Leading Sponsors
5.5 Clinical Trials: Leading Industry Sponsors
5.6 Trends in Trial Design
6 Deal-making Trends
6.1 Deal-making Trends
7 Social Media Trends
7.1 Key Twitter Chatter
7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve
8 Key Findings
8.1 Key Findings
9 Appendix
9.1 Sources
9.2 Methodology
9.3 About the Authors
10 About the Publisher
10.1 Contact

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Moderna